BNP Paribas Financial Markets Boosts Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

BNP Paribas Financial Markets boosted its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCTFree Report) by 3.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 23,259 shares of the biotechnology company’s stock after purchasing an additional 682 shares during the period. BNP Paribas Financial Markets owned approximately 0.09% of Arcturus Therapeutics worth $733,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Jupiter Asset Management Ltd. acquired a new stake in shares of Arcturus Therapeutics in the 3rd quarter worth approximately $4,977,000. ARK Investment Management LLC grew its holdings in shares of Arcturus Therapeutics by 7.7% during the 4th quarter. ARK Investment Management LLC now owns 2,047,687 shares of the biotechnology company’s stock worth $64,564,000 after purchasing an additional 146,141 shares during the period. AQR Capital Management LLC raised its stake in shares of Arcturus Therapeutics by 239.8% in the 3rd quarter. AQR Capital Management LLC now owns 172,202 shares of the biotechnology company’s stock valued at $4,400,000 after acquiring an additional 121,526 shares during the period. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Arcturus Therapeutics in the third quarter worth about $2,738,000. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Arcturus Therapeutics by 224.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 114,810 shares of the biotechnology company’s stock worth $3,620,000 after purchasing an additional 79,387 shares in the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Arcturus Therapeutics news, COO Pad Chivukula sold 8,565 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $35.01, for a total transaction of $299,860.65. Following the completion of the transaction, the chief operating officer now owns 490,883 shares in the company, valued at approximately $17,185,813.83. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 13.80% of the company’s stock.

Arcturus Therapeutics Stock Performance

Shares of ARCT stock opened at $38.48 on Friday. Arcturus Therapeutics Holdings Inc. has a 52-week low of $17.52 and a 52-week high of $43.81. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of -9.84 and a beta of 2.65. The firm’s 50-day moving average is $30.19 and its 200-day moving average is $31.38.

Arcturus Therapeutics (NASDAQ:ARCTGet Free Report) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.17) by $0.17. The business had revenue of $38.01 million for the quarter, compared to the consensus estimate of $22.12 million. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. Sell-side analysts predict that Arcturus Therapeutics Holdings Inc. will post -4.39 EPS for the current fiscal year.

Analyst Ratings Changes

ARCT has been the subject of several recent analyst reports. William Blair reissued an “outperform” rating on shares of Arcturus Therapeutics in a report on Thursday, May 23rd. Citigroup lifted their price objective on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a research note on Thursday, February 8th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Arcturus Therapeutics in a report on Wednesday, March 20th. Finally, Canaccord Genuity Group cut their target price on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Arcturus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $64.86.

View Our Latest Report on ARCT

About Arcturus Therapeutics

(Free Report)

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

Further Reading

Institutional Ownership by Quarter for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.